Suchergebnisse
10
Alles
Such-Filter
Organisationen
Olema Pharmaceuticals, Inc.
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
25. März 2025 16:31 ET
|
Olema Oncology
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, at the 2025 AACR Annual Meeting
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
18. März 2025 16:01 ET
|
Olema Oncology
Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in 2026Pivotal Phase 3 OPERA-02 trial of palazestrant in...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. März 2025 16:30 ET
|
Olema Oncology
SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
19. Februar 2025 16:30 ET
|
Olema Oncology
SAN FRANCISCO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
18. Februar 2025 07:00 ET
|
Olema Oncology
SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. Februar 2025 16:30 ET
|
Olema Oncology
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology to Participate in Upcoming Investor Conferences
03. Februar 2025 16:30 ET
|
Olema Oncology
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03. Januar 2025 16:30 ET
|
Olema Oncology
SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
02. Januar 2025 07:00 ET
|
Olema Oncology
SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
10. Dezember 2024 07:00 ET
|
Olema Oncology
Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with...